COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > Final Copy Published

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Sep 12, 2024 1:54pm

49 Views

Post# 36220732

RE:RE:Final Copy Published

Could have implications for a wound healing franchise.

Ai can hallucinate but here's one take:

Enhanced Macrophage Uptake

The integration of avenanthramides into YBG could leverage the enhanced phagocytic activity observed in M2-like macrophages. These macrophages are associated with tissue repair and anti-inflammatory responses, making them ideal targets for delivering therapeutic agents. The increased uptake of YBG by M2 macrophages suggests that this delivery system could effectively transport avenanthramides to sites of inflammation or tissue damage, promoting healing and reducing chronic inflammation.

<< Previous

Bullboard Posts

Next >>

Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed